In 1990, researchers at the Max Planck Institute first isolated NT-3.263 NT-3 administration has the most beneficial effect on the CST, and axonal sprouting is not observed in other tracts, such as the cerebrospinal and rubrospinal tracts.264 Current NT-3-based clinical trials mainly focus on neuropathic pain and allodynia-related peripheral neuropathies.264,265 NT-3 inhibits the degeneration of peripheral sensory axons and improves their functions. This evidence concerns the gene NTF3 and peripheral neuropathy.